Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets.
Delivering the Power of T cells to Cancer Patients
Get to know Immatics Biotechnologies
Headquartered in: Tübingen, Germany
Founded in: 2000
Sector: Biotechnology, Medical, Therapeutics
Investor: Private Investor Network, Industrial Tech Fund
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.